Bone Marrow Transplant Rejection - Pipeline Review, H1 2018

  • ID: 4473091
  • Drug Pipelines
  • 483 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Capricor Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Kamada Ltd
  • OncoImmune Inc
  • Targazyme Inc
  • MORE
Bone Marrow Transplant Rejection - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2018, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 8, 27, 12, 47, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 13 and 1 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Capricor Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Kamada Ltd
  • OncoImmune Inc
  • Targazyme Inc
  • MORE
Introduction

Bone Marrow Transplant Rejection - Overview

Bone Marrow Transplant Rejection - Therapeutics Development

Bone Marrow Transplant Rejection - Therapeutics Assessment

Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development

Bone Marrow Transplant Rejection - Drug Profiles

Bone Marrow Transplant Rejection - Dormant Projects

Bone Marrow Transplant Rejection - Discontinued Products

Bone Marrow Transplant Rejection - Product Development Milestones

Appendix

List of Tables:

Number of Products under Development for Bone Marrow Transplant Rejection, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by AbGenomics International Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Amgen Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Amunix Operating Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by AnaptysBio Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by apceth Biopharma GmbH, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Aptevo Therapeutics Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by arGEN-X BV, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Athersys Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Biogen Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Bristol-Myers Squibb Co, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Capricor Therapeutics Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Cell Source Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Cell2B Advanced Therapeutics SA, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Cellect Biotechnology Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Compugen Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by CSL Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Cynata Therapeutics Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Cytodyn Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Elsalys Biotech SAS, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Enlivex Therapeutics Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Escape Therapeutics Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Fate Therapeutics Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Generon (Shanghai) Corp Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Gilead Sciences Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by GlaxoSmithKline Plc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Heat Biologics Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Incyte Corp, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Inspyr Therapeutics Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Jazz Pharmaceuticals Plc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Johnson & Johnson, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Kadmon Corp LLC, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Kamada Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Kiadis Pharma NV, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Kymab Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by LG Chem Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by MaaT Pharma, H1 2018

Bone Marrow Transplant Rejection - Pipeline by MacroGenics Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by MallInckrodt Plc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Mesoblast Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Nohla Therapeutics Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Novartis AG, H1 2018

Bone Marrow Transplant Rejection - Pipeline by OncoImmune Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Pfizer Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Pharmicell Co Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Pluristem Therapeutics Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by REGiMMUNE Corp, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Sanofi, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Sarepta Therapeutics Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Seattle Genetics Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Seres Therapeutics Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Sigmoid Pharma Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Taiga Biotechnologies Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Targazyme Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by TC BioPharm Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by TxCell SA, H1 2018

Bone Marrow Transplant Rejection - Pipeline by United BioPharma Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Vault Pharma Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by VBI Vaccines Inc, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Xenikos BV, H1 2018

Bone Marrow Transplant Rejection - Pipeline by XL-protein GmbH, H1 2018

Bone Marrow Transplant Rejection - Pipeline by Zai Lab Ltd, H1 2018

Bone Marrow Transplant Rejection - Pipeline by ZIOPHARM Oncology Inc, H1 2018

Bone Marrow Transplant Rejection - Dormant Projects, H1 2018

Bone Marrow Transplant Rejection - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Bone Marrow Transplant Rejection, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • AbGenomics International Inc
  • Amgen Inc
  • Amunix Operating Inc
  • AnaptysBio Inc
  • apceth Biopharma GmbH
  • Aptevo Therapeutics Inc
  • arGEN-X BV
  • Athersys Inc
  • Bellicum Pharmaceuticals Inc
  • Biogen Inc
  • Bristol-Myers Squibb Co
  • Capricor Therapeutics Inc
  • Cell Source Inc
  • Cell2B Advanced Therapeutics SA
  • Cellect Biotechnology Ltd
  • Compugen Ltd
  • CSL Ltd
  • Cynata Therapeutics Ltd
  • Cytodyn Inc
  • Elsalys Biotech SAS
  • Enlivex Therapeutics Ltd
  • Escape Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Generon (Shanghai) Corp Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Heat Biologics Inc
  • Incyte Corp
  • Inspyr Therapeutics Inc
  • Jazz Pharmaceuticals Plc
  • Johnson & Johnson
  • Kadmon Corp LLC
  • Kamada Ltd
  • Kiadis Pharma NV
  • Kymab Ltd
  • LG Chem Ltd
  • MaaT Pharma
  • MacroGenics Inc
  • MallInckrodt Plc
  • Mesoblast Ltd
  • Millennium Pharmaceuticals Inc
  • Nohla Therapeutics Inc
  • Novartis AG
  • OncoImmune Inc
  • Pfizer Inc
  • Pharmicell Co Ltd
  • Pluristem Therapeutics Inc
  • REGiMMUNE Corp
  • Sanofi
  • Sarepta Therapeutics Inc
  • Seattle Genetics Inc
  • Seres Therapeutics Inc
  • Sigmoid Pharma Ltd
  • Taiga Biotechnologies Inc
  • Takeda Pharmaceutical Co Ltd
  • Targazyme Inc
  • TC BioPharm Ltd
  • TxCell SA
  • United BioPharma Inc
  • Vault Pharma Inc
  • VBI Vaccines Inc
  • Xenikos BV
  • XL-protein GmbH
  • Zai Lab Ltd
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll